- Home
- SNCR vs VTVT Comparison
SNCR vs VTVT Comparison
Compare SNCR & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- VTVT
- Stock Information
- Founded
- SNCR 2000
- VTVT 2015
- Country
- SNCR United States
- VTVT United States
- Employees
- SNCR N/A
- VTVT N/A
- Industry
- SNCR EDP Services
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- VTVT Health Care
- Exchange
- SNCR Nasdaq
- VTVT Nasdaq
- Market Cap
- SNCR 61.5M
- VTVT 54.4M
- IPO Year
- SNCR 2006
- VTVT 2015
- Fundamental
- Price
- SNCR $4.99
- VTVT $21.07
- Analyst Decision
- SNCR Strong Buy
- VTVT Strong Buy
- Analyst Count
- SNCR 1
- VTVT 2
- Target Price
- SNCR $13.00
- VTVT $35.50
- AVG Volume (30 Days)
- SNCR 69.4K
- VTVT 4.4K
- Earning Date
- SNCR 11-04-2025
- VTVT 11-12-2025
- Dividend Yield
- SNCR N/A
- VTVT N/A
- EPS Growth
- SNCR N/A
- VTVT N/A
- EPS
- SNCR N/A
- VTVT N/A
- Revenue
- SNCR $171,870,000.00
- VTVT $17,000.00
- Revenue This Year
- SNCR $1.36
- VTVT N/A
- Revenue Next Year
- SNCR $5.22
- VTVT N/A
- P/E Ratio
- SNCR N/A
- VTVT N/A
- Revenue Growth
- SNCR 2.54
- VTVT N/A
- 52 Week Low
- SNCR $4.83
- VTVT $12.62
- 52 Week High
- SNCR $12.85
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- SNCR 36.60
- VTVT 50.20
- Support Level
- SNCR $4.83
- VTVT $20.19
- Resistance Level
- SNCR $5.31
- VTVT $21.99
- Average True Range (ATR)
- SNCR 0.27
- VTVT 1.06
- MACD
- SNCR 0.01
- VTVT -0.25
- Stochastic Oscillator
- SNCR 16.50
- VTVT 39.08
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.